In recent years, immunotherapy using immune checkpoint inhibitors (ICIs), mainly against programmed cell death receptor-1 (PD-1) or its ligand, PD-L1, has been one of the biggest advances in the treatment of GC. The gene discussed is CD274; the disease is gastric cancer.